<DOC>
	<DOCNO>NCT00215462</DOCNO>
	<brief_summary>The purpose study collect anti-tumor activity vinorelbine give patient esophageal gastric tumor . We also collect information toxicity vinorelbine patient .</brief_summary>
	<brief_title>Vinorelbine Unresectable Metastatic Esophageal Gastric Adenocarcinoma</brief_title>
	<detailed_description>- Patients receive vinorelbine intravenously per week eight week . These treatment repeat initial eight week long patient continue receive benefit treatment . If patient experience significant toxicity , dose may reduce chemotherapy may discontinue . - Before begin treatment therapy , routine laboratory test , scan x-rays do check body 's response treatment . A physical exam do start study course treatment . Scans do eight week therapy . - Patients remain study long disease become bad experience severe side effect .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Locally unresectable metastatic esophageal adenocarcinoma . Locally unresectable metastatic gastric adenocarcinoma . Only patient measurable tumor eligible . No one prior chemotherapy regimen ECOG performance status 01 Life expectancy &gt; 12 week Greater equal 1,200 calorie/day intake ANC &gt; 1,500/mm3 AST &lt; 3 x ULN Total bilirubin &lt; 2.0 ng/dl Platelets &gt; 100,000/mm3 Serum creatinine &lt; 2.0 mg/dl Prior therapy vinca alkaloid Chemotherapy within past three week Clinically apparent central nervous system metastases carcinomatous meningitis Peripheral neuropathy &gt; 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>gastric adenocarcinoma</keyword>
	<keyword>esophageal adenocarcinoma</keyword>
	<keyword>vinorelbine</keyword>
</DOC>